Cultivated Enterococcus faecium B6 from children with obesity promotes nonalcoholic fatty liver disease by the bioactive metabolite tyramine

References

• Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, Swain MG, Congly SE, Kaplan GG, Shaheen A-A. et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–25. doi:10.1016/S2468-1253(22)00165-0.
   PubMed Web of Science ®Google Scholar
• Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, Tan DJH, Tang ASP, Tay P, Xiao J. et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20–30. doi:10.1016/S2468-1253(22)00317-X.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, She Z-G, Zhu L, Cai J, Li H. et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71(5):1851–1864. doi:10.1002/hep.31150.
   PubMed Web of Science ®Google Scholar
• Nobili V, Alisi A, Valenti L, Miele L, Feldstein AE, Alkhouri N. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol. 2019;16(9):517–530. doi:10.1038/s41575-019-0169-z.
   PubMed Web of Science ®Google Scholar
• Paik JM, Kabbara K, Eberly KE, Younossi Y, Henry L, Younossi ZM. Global burden of NAFLD and chronic liver disease among adolescents and young adults. Hepatology. 2022;75(5):1204–1217. doi:10.1002/hep.32228.
   PubMed Web of Science ®Google Scholar
• Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP. et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. J Hepatol. 2018;69(4):896–904. doi:10.1016/j.jhep.2018.05.036.
   PubMed Web of Science ®Google Scholar
• Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology. 1998;114(4):842–845. doi:10.1016/S0016-5085(98)70599-2.
   PubMed Web of Science ®Google Scholar
• Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. doi:10.1038/s41591-018-0104-9.
   PubMed Web of Science ®Google Scholar
• Yu Y, Cai J, She Z, Li H. Insights into the epidemiology, pathogenesis, and therapeutics of nonalcoholic fatty liver diseases. Adv Sci (Weinh). 2019;6(4):1801585. doi:10.1002/advs.201801585.
   PubMedGoogle Scholar
• Zhao Y, Zhou J, Liu J, Wang Z, Chen M, Zhou S. Metagenome of gut microbiota of children with nonalcoholic fatty liver disease. Front Pediatr. 2019;7:518. doi:10.3389/fped.2019.00518.
   PubMed Web of Science ®Google Scholar
• Monga Kravetz A, Testerman T, Galuppo B, Graf J, Pierpont B, Siebel S, Feinn R, Santoro N. Effect of gut microbiota and PNPLA3 rs738409 variant on nonalcoholic fatty liver disease (NAFLD) in obese youth. J Clin Endocrinol Metab. 2020;105(10):e3575–85. doi:10.1210/clinem/dgaa382.
   PubMed Web of Science ®Google Scholar
• Tokuhara D. Role of the gut microbiota in regulating Non-alcoholic fatty liver disease in children and adolescents. Front Nutr. 2021;8:700058. doi:10.3389/fnut.2021.700058.
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57(2):601–609. doi:10.1002/hep.26093.
   PubMed Web of Science ®Google Scholar
• Michail S, Lin M, Frey MR, Fanter R, Paliy O, Hilbush B, Reo NV. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91(2):1–9. doi:10.1093/femsec/fiu002.
   PubMed Web of Science ®Google Scholar
• Pafili K, Roden M. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab. 2021;50:101122. doi:10.1016/j.molmet.2020.101122.
   PubMed Web of Science ®Google Scholar
• Gomes AC, Hoffmann C, Mota JF. The human gut microbiota: metabolism and perspective in obesity. Gut Microbes. 2018;9:308–325. doi:10.1080/19490976.2018.1465157.
   PubMed Web of Science ®Google Scholar
• Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, Bross C, Durelle J, Goyal NP, Hamilton G. et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology. 2019;157(4):1109–1122. doi:10.1053/j.gastro.2019.06.028.
   PubMed Web of Science ®Google Scholar
• Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G. et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019;30(4):675–88.e7. doi:10.1016/j.cmet.2019.08.018.
   PubMed Web of Science ®Google Scholar
• Caussy C, Hsu C, Lo MT, Liu A, Bettencourt R, Ajmera VH, Bassirian S, Hooker J, Sy E, Richards L. et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology. 2018;68(3):918–932. doi:10.1002/hep.29892.
   PubMed Web of Science ®Google Scholar
• Hoyles L, Fernández-Real JM, Federici M, Serino M, Abbott J, Charpentier J, Heymes C, Luque JL, Anthony E, Barton RH. et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat Med. 2018;24(7):1070–1080. doi:10.1038/s41591-018-0061-3.
   PubMed Web of Science ®Google Scholar
• Chen YM, Liu Y, Zhou RF, Chen XL, Wang C, Tan XY, Wang L-J, Zheng R-D, Zhang H-W, Ling W-H. et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci Rep. 2016;6(1):19076. doi:10.1038/srep19076.
   PubMedGoogle Scholar
• Chu H, Duan Y, Yang L, Schnabl B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut. 2019;68(2):359–370. doi:10.1136/gutjnl-2018-316307.
   PubMed Web of Science ®Google Scholar
• Zeybel M, Arif M, Li X, Altay O, Yang H, Shi M, Akyildiz M, Saglam B, Gonenli MG, Yigit B. et al. Multiomics analysis reveals the impact of microbiota on host metabolism in hepatic steatosis. Adv Sci (Weinh). 2022;9(11):e2104373. doi:10.1002/advs.202104373.
   PubMedGoogle Scholar
• Pugin B, Barcik W, Westermann P, Heider A, Wawrzyniak M, Hellings P, Akdis CA, O’Mahony L. A wide diversity of bacteria from the human gut produces and degrades biogenic amines. Microb Ecol Health Dis. 2017;28(1):1353881. doi:10.1080/16512235.2017.1353881.
   PubMedGoogle Scholar
• Laursen MF, Sakanaka M, von Burg N, Mörbe U, Andersen D, Moll JM, Pekmez CT, Rivollier A, Michaelsen KF, Mølgaard C. et al. Bifidobacterium species associated with breastfeeding produce aromatic lactic acids in the infant gut. Nat Microbiol. 2021;6(11):1367–1382. doi:10.1038/s41564-021-00970-4.
   PubMed Web of Science ®Google Scholar
• Murooka Y, Higashiura T, Harada T. Genetic mapping of tyramine oxidase and arylsulfatase genes and their regulation in intergeneric hybrids of enteric bacteria. J Bacteriol. 1978;136(2):714–722. doi:10.1128/jb.136.2.714-722.1978.
   PubMed Web of Science ®Google Scholar
• Connil N, Le Breton Y, Dousset X, Auffray Y, Rincé A, Prévost H. Identification of the Enterococcus faecalis tyrosine decarboxylase operon involved in tyramine production. Appl Environ Microbiol. 2002;68(7):3537–3544. doi:10.1128/AEM.68.7.3537-3544.2002.
   PubMed Web of Science ®Google Scholar
• Liu R, Hong J, Xu X, Feng Q, Zhang D, Gu Y, Shi J, Zhao S, Liu W, Wang X. et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017;23(7):859–868. doi:10.1038/nm.4358.
   PubMed Web of Science ®Google Scholar
• O’Donnell MP, Fox BW, Chao PH, Schroeder FC, Sengupta P. A neurotransmitter produced by gut bacteria modulates host sensory behaviour. Nature. 2020;583(7816):415–420. doi:10.1038/s41586-020-2395-5.
   PubMed Web of Science ®Google Scholar
• Tomita H, Yokooji Y, Ishibashi T, Imanaka T, Atomi H. An archaeal glutamate decarboxylase homolog functions as an aspartate decarboxylase and is involved in β-alanine and coenzyme a biosynthesis. J Bacteriol. 2014;196(6):1222–1230. doi:10.1128/JB.01327-13.
   PubMed Web of Science ®Google Scholar
• Patel A, Thompson A, Abdelmalek L, Adams-Huet B, Jialal I. The relationship between tyramine levels and inflammation in metabolic syndrome. Horm Mol Biol Clin Investig. 2019;40(1):40. doi:10.1515/hmbci-2019-0047.
   Web of Science ®Google Scholar
• Yang JH, Byeon EH, Kang D, Hong SG, Yang J, Kim DR, Yun S-P, Park S-W, Kim H-J, Huh J-W. et al. Fermented soybean paste attenuates biogenic amine-induced liver damage in obese mice. Cells. 2023;12(5):12. doi:10.3390/cells12050822.
   Web of Science ®Google Scholar
• Quan LH, Zhang C, Dong M, Jiang J, Xu H, Yan C, Liu X, Zhou H, Zhang H, Chen L. et al. Myristoleic acid produced by enterococci reduces obesity through brown adipose tissue activation. Gut. 2020;69(7):1239–1247. doi:10.1136/gutjnl-2019-319114.
   PubMed Web of Science ®Google Scholar
• Lang S, Demir M, Duan Y, Martin A, Schnabl B. Cytolysin-positive Enterococcus faecalis is not increased in patients with non-alcoholic steatohepatitis. Liver Int. 2020;40(4):860–865. doi:10.1111/liv.14377.
   PubMed Web of Science ®Google Scholar
• Oh JH, Lee JH, Cho MS, Kim H, Chun J, Lee JH, Yoon Y, Kang W. Characterization of gut microbiome in Korean patients with metabolic associated fatty liver disease. Nutrients. 2021;13(3):1013. doi:10.3390/nu13031013.
   PubMed Web of Science ®Google Scholar
• Korobeinikova AV, Zlobovskaya OA, Sheptulina AF, Ashniev GA, Bobrova MM, Yafarova AA, Akasheva DU, Kabieva SS, Bakoev SY, Zagaynova AV. et al. Gut microbiota patterns in patients with non-alcoholic fatty liver disease: a comprehensive assessment using three analysis methods. Int J Mol Sci. 2023;24(20):24. doi:10.3390/ijms242015272.
   Web of Science ®Google Scholar
• Brown K, Thomson CA, Wacker S, Drikic M, Groves R, Fan V, Lewis IA, McCoy KD. Microbiota alters the metabolome in an age- and sex- dependent manner in mice. Nat Commun. 2023;14(1):1348. doi:10.1038/s41467-023-37055-1.
   PubMed Web of Science ®Google Scholar
• Yang M, Qi X, Li N, Kaifi JT, Chen S, Wheeler AA, Kimchi ET, Ericsson AC, Rector RS, Staveley-O’Carroll KF. et al. Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol. Nat Commun. 2023;14(1):228. doi:10.1038/s41467-023-35861-1.
   PubMed Web of Science ®Google Scholar
• De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107(33):14691–14696. doi:10.1073/pnas.1005963107.
   PubMed Web of Science ®Google Scholar
• Pan X, Kaminga AC, Liu A, Wen SW, Luo M. Gut microbiota, glucose, lipid, and water-electrolyte metabolism in children with nonalcoholic fatty liver disease. Front Cell Infect Microbiol. 2021;11:683743. doi:10.3389/fcimb.2021.683743.
   PubMed Web of Science ®Google Scholar
• Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63(3):764–775. doi:10.1002/hep.28356.
   PubMed Web of Science ®Google Scholar
• Del Chierico F, Nobili V, Vernocchi P, Russo A, De Stefanis C, Gnani D, Furlanello C, Zandonà A, Paci P, Capuani G. et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology. 2017;65(2):451–464. doi:10.1002/hep.28572.
   PubMed Web of Science ®Google Scholar
• Van Hul M, Cani PD. The gut microbiota in obesity and weight management: microbes as friends or foe? Nat Rev Endocrinol. 2023;19(5):258–271. doi:10.1038/s41574-022-00794-0.
   PubMed Web of Science ®Google Scholar
• Wei M, Huang F, Zhao L, Zhang Y, Yang W, Wang S, Li M, Han X, Ge K, Qu C. et al. A dysregulated bile acid-gut microbiota axis contributes to obesity susceptibility. EBioMedicine. 2020;55:102766. doi:10.1016/j.ebiom.2020.102766.
   PubMed Web of Science ®Google Scholar
• Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, Bugianesi E, Sirlin CB, Neuschwander-Tetri BA, Rinella ME. et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1(1):15080. doi:10.1038/nrdp.2015.80.
   PubMedGoogle Scholar
• Xu M, Tan J, Zhu L, Ge C, Zhang Y, Gao F, Dai X, Kuang Q, Chai J, Zou B. et al. Palmitoyltransferase ZDHHC3 aggravates nonalcoholic steatohepatitis by targeting S-Palmitoylated IRHOM2. Adv Sci (Weinh). 2023;10(28):e2302130. doi:10.1002/advs.202302130.
   PubMedGoogle Scholar
• Nakahara T, Hyogo H, Ono A, Nagaoki Y, Kawaoka T, Miki D, Tsuge M, Hiraga N, Hayes CN, Hiramatsu A. et al. Involvement of porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease. J Gastroenterol. 2018;53(2):269–280. doi:10.1007/s00535-017-1368-4.
   PubMed Web of Science ®Google Scholar
• Fei N, Bruneau A, Zhang X, Wang R, Wang J, Rabot S, Gérard P, Zhao L. Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease. mBio. 2020;11(1):11. doi:10.1128/mBio.03263-19.
   Web of Science ®Google Scholar
• Xin FZ, Zhao ZH, Liu XL, Pan Q, Wang ZX, Zeng L, Zhang Q-R, Ye L, Wang M-Y, Zhang R-N. et al. Escherichia fergusonii promotes nonobese nonalcoholic fatty liver disease by interfering with host hepatic lipid metabolism through its own msRNA 23487. Cell Mol Gastroenterol Hepatol. 2022;13(3):827–841. doi:10.1016/j.jcmgh.2021.12.003.
   PubMed Web of Science ®Google Scholar
• Natividad JM, Lamas B, Pham HP, Michel ML, Rainteau D, Bridonneau C, da Costa G, van Hylckama Vlieg J, Sovran B, Chamignon C. et al. Bilophila wadsworthia aggravates high fat diet induced metabolic dysfunctions in mice. Nat Commun. 2018;9(1):2802. doi:10.1038/s41467-018-05249-7.
   PubMed Web of Science ®Google Scholar
• Greenblum S, Carr R, Borenstein E. Extensive strain-level copy-number variation across human gut microbiome species. Cell. 2015;160(4):583–594. doi:10.1016/j.cell.2014.12.038.
   PubMed Web of Science ®Google Scholar
• Wei M, Gu E, Luo J, Zhang Z, Xu D, Tao X, Shah NP, Wei H. Enterococcus hirae WEHI01 isolated from a healthy Chinese infant ameliorates the symptoms of type 2 diabetes by elevating the abundance of Lactobacillales in rats. J Dairy Sci. 2020;103(4):2969–2981. doi:10.3168/jds.2019-17185.
   PubMed Web of Science ®Google Scholar
• Jiang J, Xiong J, Ni J, Chen C, Wang K. Live combined B. subtilis and E. faecium alleviate liver inflammation, improve intestinal barrier function, and modulate gut microbiota in mice with non-alcoholic fatty liver disease. Med Sci Monit. 2021;27:e931143. doi:10.12659/MSM.931143.
   PubMed Web of Science ®Google Scholar
• Duan Y, Llorente C, Lang S, Brandl K, Chu H, Jiang L, White RC, Clarke TH, Nguyen K, Torralba M. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019;575(7783):505–511. doi:10.1038/s41586-019-1742-x.
   PubMed Web of Science ®Google Scholar
• Nunez N, Derré-Bobillot A, Trainel N, Lakisic G, Lecomte A, Mercier-Nomé F, Cassard A-M, Bierne H, Serror P, Archambaud C. et al. The unforeseen intracellular lifestyle of Enterococcus faecalis in hepatocytes. Gut Microbes. 2022;14(1):2058851. doi:10.1080/19490976.2022.2058851.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liang Y, Jiang J, Lu C, Shi F, Cao Q, Zhang Y, Diao H. A high-salt diet exacerbates liver fibrosis through enterococcus-dependent macrophage activation. Microbiol Spectr. 2023;11(2):e0340322. doi:10.1128/spectrum.03403-22.
   PubMed Web of Science ®Google Scholar
• Grimaldi B, Bellet MM, Katada S, Astarita G, Hirayama J, Amin RH, Granneman JG, Piomelli D, Leff T, Sassone-Corsi P. et al. PER2 controls lipid metabolism by direct regulation of PPARγ. Cell Metab. 2010;12(5):509–520. doi:10.1016/j.cmet.2010.10.005.
   PubMed Web of Science ®Google Scholar
• Francque S, Szabo G, Abdelmalek MF, Byrne CD, Cusi K, Dufour JF, Roden M, Sacks F, Tacke F. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nat Rev Gastroenterol Hepatol. 2021;18(1):24–39. doi:10.1038/s41575-020-00366-5.
   PubMed Web of Science ®Google Scholar
• Khan RS, Bril F, Cusi K, Newsome PN. Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology. 2019;70(2):711–724. doi:10.1002/hep.30429.
   PubMed Web of Science ®Google Scholar
• Piccinin E, Villani G, Moschetta A. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators. Nat Rev Gastroenterol Hepatol. 2019;16(3):160–174. doi:10.1038/s41575-018-0089-3.
   PubMed Web of Science ®Google Scholar
• Pettinelli P, Videla LA. Up-regulation of PPAR-γ mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab. 2011;96(5):1424–1430. doi:10.1210/jc.2010-2129.
   PubMed Web of Science ®Google Scholar
• Zhou J, Febbraio M, Wada T, Zhai Y, Kuruba R, He J, Lee JH, Khadem S, Ren S, Li S. et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARγ in promoting steatosis. Gastroenterology. 2008;134(2):556–567. doi:10.1053/j.gastro.2007.11.037.
   PubMed Web of Science ®Google Scholar
• Shan S, Zhou J, Yin R, Zhang L, Shi J, Qiao Q, Li Z. Millet bran protein hydrolysate displays the anti-non-alcoholic fatty liver disease effect via activating peroxisome proliferator-activated receptor γ to restrain fatty acid uptake. J Agric Food Chem. 2023;71(3):1628–1642. doi:10.1021/acs.jafc.2c08169.
   PubMed Web of Science ®Google Scholar
• Chen H, Tan H, Wan J, Zeng Y, Wang J, Wang H, Lu X. PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets. Pharmacology & Therapeutics. 2023;245:108391. doi:10.1016/j.pharmthera.2023.108391.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554. doi:10.1002/hep.27368.
   PubMed Web of Science ®Google Scholar
• Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349–364. doi:10.1038/s41575-018-0009-6.
   PubMed Web of Science ®Google Scholar
• Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenwälder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease – novel insights into cellular communication circuits. J Hepatol. 2022;77(4):1136–1160. doi:10.1016/j.jhep.2022.06.012.
   PubMed Web of Science ®Google Scholar
• Lee JH, Woo KJ, Kim MA, Hong J, Kim J, Kim SH, Han K-I, Iwasa M, Kim T-J. Heat-killed Enterococcus faecalis prevents adipogenesis and high fat diet-induced obesity by inhibition of lipid accumulation through inhibiting C/EBP-α and PPAR-γ in the insulin signaling pathway. Nutrients. 2022;14(6):14. doi:10.3390/nu14061308.
   Web of Science ®Google Scholar
• Xu W, Yu J, Yang Y, Li Z, Zhang Y, Zhang F, Wang Q, Xie Y, Zhao B, Wu C. et al. Strain-level screening of human gut microbes identifies blautia producta as a new anti-hyperlipidemic probiotic. Gut Microbes. 2023;15(1):2228045. doi:10.1080/19490976.2023.2228045.
   PubMed Web of Science ®Google Scholar
• Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease—A starter’s guide. Nutrients. 2017;9(10):1072. doi:10.3390/nu9101072.
   PubMed Web of Science ®Google Scholar
• Tilg H, Adolph TE, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications. Cell Metab. 2022;34(11):1700–1718. doi:10.1016/j.cmet.2022.09.017.
   PubMed Web of Science ®Google Scholar
• Zhu W, Gregory JC, Org E, Buffa JA, Gupta N, Wang Z, Li L, Fu X, Wu Y, Mehrabian M. et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–124. doi:10.1016/j.cell.2016.02.011.
   PubMed Web of Science ®Google Scholar
• Zhao M, Zhao L, Xiong X, He Y, Huang W, Liu Z, Ji L, Pan B, Guo X, Wang L. et al. TMAVA, a metabolite of intestinal microbes, is increased in plasma from patients with liver steatosis, inhibits γ-butyrobetaine hydroxylase, and exacerbates fatty liver in mice. Gastroenterology. 2020;158(8):2266–81.e27. doi:10.1053/j.gastro.2020.02.033.
   PubMed Web of Science ®Google Scholar
• Salter M, Kenney A. Myocardial injury from tranylcypromine-induced hypertensive crisis secondary to excessive tyramine intake. Cardiovasc Toxicol. 2018;18(6):583–586. doi:10.1007/s12012-018-9476-9.
   PubMed Web of Science ®Google Scholar
• Marcobal A, Martín-Alvarez PJ, Moreno-Arribas MV, Muñoz R. A multifactorial design for studying factors influencing growth and tyramine production of the lactic acid bacteria lactobacillus brevis CECT 4669 and Enterococcus faecium BIFI-58. Res Microbiol. 2006;157(5):417–424. doi:10.1016/j.resmic.2005.11.006.
   PubMed Web of Science ®Google Scholar
• Gu C, Zhou Z, Yu Z, He M, He L, Luo Z, Xiao W, Yang Q, Zhao F, Li W. et al. The microbiota and it’s correlation with metabolites in the gut of mice with nonalcoholic fatty liver disease. Front Cell Infect Microbiol. 2022;12:870785. doi:10.3389/fcimb.2022.870785.
   PubMed Web of Science ®Google Scholar
• Nagatsu T. Progress in monoamine oxidase (MAO) research in relation to genetic engineering. Neurotoxicology. 2004;25(1–2):11–20. doi:10.1016/S0161-813X(03)00085-8.
   PubMed Web of Science ®Google Scholar
• Faraj BA, Fulenwider JT, Rypins EB, Nordlinger B, Ivey GL, Jansen RD, Ali FM, Camp VM, Kutner M, Schmidt F. et al. Tyramine kinetics and metabolism in cirrhosis. J Clin Invest. 1979;64(2):413–420. doi:10.1172/JCI109477.
   PubMed Web of Science ®Google Scholar
• Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, Smith S, Greenwood R, Sikaroodi M, Lam V, Crotty P. et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2013;11(7):868–75.e1–3. doi:10.1016/j.cgh.2013.02.015.
   Web of Science ®Google Scholar
• Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020;17(5):279–297. doi:10.1038/s41575-020-0269-9.
   PubMed Web of Science ®Google Scholar
• Iino C, Endo T, Mikami K, Hasegawa T, Kimura M, Sawada N, Nakaji S, Fukuda S. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: a large BMI- and sex-matched population study. Hepatol Int. 2019;13(6):748–756. doi:10.1007/s12072-019-09987-8.
   PubMed Web of Science ®Google Scholar
• Zhou XL, Fu JF. Expert consensus on diagnosis and treatment of nonalcoholic fatty liver disease in children. Chin J Pract Pediat. 2018;33:487–492.
   Google Scholar
• Wei J, Dai W, Pan X, Yang F, Luo J, Luo M. Isolation and identification of commensal gut bacterial strains with lipogenic effects contributing to NAFLD in children. iScience. 2024;27(2):108861.doi: 10.1016/j.isci.2024.108861.
   PubMed Web of Science ®Google Scholar
• Wei J, Dai W, Pan X, Zhong Y, Xu N, Ye P, Wang J, Li J, Yang F, Luo J. et al. Identifying the novel gut microbial metabolite contributing to metabolic syndrome in children based on integrative analyses of microbiome-metabolome signatures. Microbiol Spectr. 2023;11(2):e0377122. doi:10.1128/spectrum.03771-22.
   PubMed Web of Science ®Google Scholar